Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Lemery, 2017, First FDA approval agnostic of cancer site – when a biomarker defines the indication, N Engl J Med, 377, 1409, 10.1056/NEJMp1709968 Weber, 2017, Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, N Engl J Med, 377, 1824, 10.1056/NEJMoa1709030 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial, Lancet, 390, 2461, 10.1016/S0140-6736(17)31827-5 Sun, 2018, Regulation and function of the PD-L1 checkpoint, Immunity, 48, 434, 10.1016/j.immuni.2018.03.014 Nishimura, 2001, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, 291, 319, 10.1126/science.291.5502.319 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8 Gianchechi, 2013, Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity, Autoimmun Rev, 12, 1091, 10.1016/j.autrev.2013.05.003 Trautmann, 2006, Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, Nat Med, 12, 1198, 10.1038/nm1482 Urbani, 2006, PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion, J Virol, 80, 11398, 10.1128/JVI.01177-06 Peng, 2008, PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients, Mol Immunol, 45, 963, 10.1016/j.molimm.2007.07.038 Yang, 2008, Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy, Circulation, 117, 660, 10.1161/CIRCULATIONAHA.107.741025 Wang, 2007, Programmed cell death (PD-1) and its ligand PD-L1 are required for allograft tolerance, Eur J Immunol, 37, 2983, 10.1002/eji.200737583 Tanaka, 2007, PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection, J Immunol, 179, 5204, 10.4049/jimmunol.179.8.5204 Engels, 2008, Cancer risk in people infected with human immunodeficiency virus in the United States, Int J Cancer, 123, 187, 10.1002/ijc.23487 Engels, 2011, Spectrum of cancer risk among US solid organ transplant recipients, JAMA, 306, 1891, 10.1001/jama.2011.1592 Perz, 2006, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, J Hepatol, 45, 529, 10.1016/j.jhep.2006.05.013 Menzies, 2017, Anti-Pd-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Ann Oncol, 28, 368, 10.1093/annonc/mdw443 Gutzmer, 2017, Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity, Eur J Cancer, 75, 24, 10.1016/j.ejca.2016.12.038 Leonardi, 2018, Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders, J Clin Oncol, 36, 1905, 10.1200/JCO.2017.77.0305 Organ procurement and transplantation network. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#. [Accessed 11 May 2018]. Bonacci, 2016, Simplified estimates of HIV and incidence and transmission rates for the USA, 2008–12, AIDS, 30, 332, 10.1097/QAD.0000000000000939 Wasley, 2010, The prevalence of hepatitis B virus infection in the United States in the era of vaccination, J Infect Dis, 202, 192, 10.1086/653622 Edlin, 2015, Toward a more accurate estimate of the prevalence of hepatitis C in the United States, Hepatology, 62, 1353, 10.1002/hep.27978 Kittai, 2017, Immune checkpoint inhibitors in organ transplant patients, J Immunother, 40, 277, 10.1097/CJI.0000000000000180 Uldrick, 2017, Interim safety analysis of Cancer Immunotherapy Trials Network-12 (CITN-12): a phase 1 study of pembrolizumab in patients with HIV and relapsed, refractory, or disseminated malignancies, J Immunother Cancer, 5, O40 El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Schachter, 2017, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicenter, randomized, open-label phase 3 study (KEYNOTE-006), Lancet, 390, 1853, 10.1016/S0140-6736(17)31601-X Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 377, 1345, 10.1056/NEJMoa1709684 Velu, 2009, Enhancing SIV-specific immunity in vivo by PD-1 blockade, Nature, 458, 206, 10.1038/nature07662 Seung, 2013, PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads, PLoS One, 8, 10.1371/journal.pone.0077780 Finnefrock, 2009, PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination, J Immunol, 182, 980, 10.4049/jimmunol.182.2.980 Guihot, 2018, Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer, Ann Oncol, 29, 517, 10.1093/annonc/mdx696 Tzeng, 2012, PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model, PLoS One, 7, 10.1371/journal.pone.0039179 Gardiner, 2013, A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection, PLoS One, 8, 10.1371/journal.pone.0063818 Schvartsman, 2017, Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma, Ann Intern Med, 167, 361, 10.7326/L17-0187 Koksal, 2017, HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma, Ann Oncol, 28, 3103, 10.1093/annonc/mdx502 Lake, 2017, Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy, AIDS, 31, 2115, 10.1097/QAD.0000000000001599 Lavole, 2018, PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?, Ann Oncol, 29, 1065, 10.1093/annonc/mdx817 Heppt, 2017, Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients, Ann Oncol, 28, 3104, 10.1093/annonc/mdx538 Wen, 2016, Safety of immune checkpoint inhibitors in Chinese patients with melanoma, Melanoma Res, 26, 284, 10.1097/CMR.0000000000000256 Kwatra, 2017, Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report, J Med Case Rep, 11, 73, 10.1186/s13256-017-1229-z Lipson, 2016, Tumor regression and allograft rejection after administration of Anti-PD-1, N Engl J Med, 374, 896, 10.1056/NEJMc1509268 Boils, 2016, Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy, Am J Transplant, 16, 2496, 10.1111/ajt.13786 Ong, 2016, Antitumor activity of nivolumab on hemodialysis after renal allograft rejection, J Immunother Cancer, 4, 64, 10.1186/s40425-016-0171-8 Herz, 2016, Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient, Eur J Cancer, 67, 66, 10.1016/j.ejca.2016.07.026 Alhamad, 2016, Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection, Am J Transplant, 16, 1332, 10.1111/ajt.13711 Winkler, 2017, Safe administration of an Anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature, J Immunother, 40, 341, 10.1097/CJI.0000000000000188 Deltcombe, 2017, Severe allograft rejection and autoimmune hemolytic anemia after Anti-PD-1 therapy in a kidney transplanted patient, Transplantation, 101 Miller, 2017, Complete pathological response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade, JAAD Case Rep, 3, 412, 10.1016/j.jdcr.2017.06.005 Barnett, 2017, Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab, N Engl J Med, 376, 191, 10.1056/NEJMc1614298 Tamain, 2016, Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma, Transpl Int, 29, 1247, 10.1111/tri.12834 Friend, 2017, Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma, Pediatr Blood Cancer, 64, 10.1002/pbc.26682 De Toni, 2017, Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient, Gastroenterology, 152, 1631, 10.1053/j.gastro.2017.01.063 Kuo, 2018, Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review, Melanoma Res, 28, 61, 10.1097/CMR.0000000000000410 Varakis, 2017, Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma, Am J Gastroenterol, 112, 1895, 10.1038/ajg.2017.387 Deleon, 2018, Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience, J Gastrointest Oncol, 1 Owonikoko, 2017, Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report, Cancer Immunol Immunother, 66, 45, 10.1007/s00262-016-1918-2 Chae, 2018, Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients, Cancer Treat Rev, 63, 116, 10.1016/j.ctrv.2017.12.004